DNA Cell Content Studies in Multiple Myeloma

References

• Shankey T. V., Ravinovitch P. S., Bagwell B., Bauer K. D., Duque R. E., Hedley D. W., Mayall B. H., Wheeless L. L. Guidelines for implementation of clinical DNA cytometry. Cytometry 1993; 14: 472–477
   PubMedGoogle Scholar
• Duque R. E., Andreef M., Braylan R. C., Diamond L. W., Peiper S. C. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 1993; 14: 492–496
   PubMedGoogle Scholar
• Durie B. G. M. Cellular and molecular genetic features of myeloma and related disordes.(1992). Hematol. Oncol. Clin. N. Am. 1992; 6: 463–477
   PubMed Web of Science ®Google Scholar
• Latreille J., Barlogie B., Dosik G., Johnston D. A., Drewinko B., Alexanian R. Cellular contents as a marker of human multiple myeloma. Blood 1980; 55: 403–408
   PubMed Web of Science ®Google Scholar
• Bunn P. A., Krasnow S., Makuch R. W., Schlam M. L., Schechter G. P. Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell Myeloma: Clinical implications. Blood 1982; 59: 528–535
   PubMed Web of Science ®Google Scholar
• Latreille J., Barlogie B., Johnston D. A., Drewinko B., Alexanian R. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 1982; 59: 43–51
   PubMed Web of Science ®Google Scholar
• Barlogie B., Alexanian R., Dixon D., Smith L., Smallwood L., Delasalle K. Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 1985; 66: 338–341
   PubMed Web of Science ®Google Scholar
• Smith L., Barlogie B., Alexanian R. Biclonal and hypodiploid multiple myeloma. Am. J. Med. 1986; 80: 841–843
   PubMed Web of Science ®Google Scholar
• Morgan R. J., Gonchoroff N. J., Katzmann J. A., Witzig T. E., Kyle R. A., Greipp P. R. Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma. Am. J. Hematol. 1989; 30: 195–200
   PubMed Web of Science ®Google Scholar
• Danova M., Riccardi A., Ucci G., Luoni R., Giordano M., Mazzini G. Ras oncogene expression and DNA content in plasma cell dyscrasias: a flow cytofluorimetric study. Br. J. Cancer 1990; 62: 781–785
   PubMed Web of Science ®Google Scholar
• Tafuri A., Meyers J., Lee B. J., Andreeff M. DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations. Cancer 1991; 67: 449–454
   PubMed Web of Science ®Google Scholar
• Tienhaara A., Pelliniemi T. T. Flow cytometric DNA analysis and clinical correlations in multiple myeloma. Am. J. Clin. Pathol. 1991; 97: 322–330
   Web of Science ®Google Scholar
• Shimazaki C., Gotoh H., Ashihara E., Oku N., Inaba T., Murakami S., Itoh K., Ura Y., Nakagawa M., Fujita N. Immunophenotype and DNA contents of myeloma cells in primary plasma cell leukemia. Am. J. Hematol. 1992; 39: 159–162
   PubMed Web of Science ®Google Scholar
• Ucci G., Petrini M., Riccardi A. Expression of p170 protein in multiple myeloma: a clinical study. Hematol Oncol. 1992; 10: 213–20
   PubMed Web of Science ®Google Scholar
• Zandecki M., Bernardi F., LaÏ J. L., Facon T., Izydorczyk V., Bauters F., Cosson A. Image analysis in multiple myeloma at diagnosis. Correlation with cytogenetic study. Cancer Genet. Cytogenet. 1994; 14: 115–9
   Web of Science ®Google Scholar
• Benchaib M., Souchier C., Ffrench M., Remy F., Bryon P. A. Fluorescence image analysis of plasma cells in monoclonal gammopathies. Anal. Quant. Cytol. Histol. 1994; 16: 137–44
   PubMed Web of Science ®Google Scholar
• De Martinis M., Ginaldi L., D'Ostilio A., Marini A., Di Genaro A., Quaglino A. Simultaneous phenotypic and kinetic analysis in multiple myeloma. Thirty-sixth annual meeting of the ASH., Nashville, TN, December, 2–61994, Abstract 2595
   Google Scholar
• Garcia-Sanz R., OrfÄO A., GonzÁLez M., Mora M. J., HernÁNdez J. M., Ortega F., Borrego D., Carnero M., Casanova F., JimÉNez R., Portero J. A., San Miguel J. F. Prognosic implications of DNA aneuploidy in a series of 156 untreated MM patients. Br. J. Haematol. 1995; 90: 106–112
   PubMed Web of Science ®Google Scholar
• Hedley D. W., Shankey T. V., Wheeless L. L. DNA Cytometry Consensus Conference. Cytometry 1993; 14: 471
   PubMedGoogle Scholar
• OrfÃO A., GonzÁLez M., Ciudad J., LÓPez-Berges M. C., LÓPez A., Vidriales B., Macedo A., San Miguel J. F. Cell cycle and DNA aneuploidy: Biological bases and terminology. DNA cytometric analysis, A. Sampedro, A. OrfÃO. Ediciones de la Universidad de Oviedo, Oviedo 1993; 13–24
   Google Scholar
• Cooke H. J., Hindley. Cloning of human satellite III DNA: different components are on differents chromosomes. J. Nucl. Acid. Res. 1979; 6: 3177–3197
   PubMed Web of Science ®Google Scholar
• Dewald G. W., Kyle R. A., Hicks G. A., Greipp P. R. P. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia or amyloidosis. Blood 1985; 66: 380–387
   PubMed Web of Science ®Google Scholar
• Facon T., Lai J. L., Nataf E., Preudhomme C., Zandecki M., Hammad M., Wattel E., Jouet J. P., Bauters F. Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients. Br. J. Haematol 1993; 84: 743–745
   PubMed Web of Science ®Google Scholar
• LaÏ J. L., Zandecki M., Mary J. Y., Bernardi F., Izydorczyk V., Flactif M., Morel P., Jouet J. P., Bauters F., Facon T. Improved cytogenetics in Multiple Mieloma. Blood 1995; 85: 2490–2497
   PubMed Web of Science ®Google Scholar
• Sawyer J. R., Waldron J. A., Jagannath S., Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet. Cytogenet. 1995, in press 1995
   Google Scholar
• Lee W., Han K., Drut R. M., Harris C. P., Meisner L. F. Use of fluorescence in situ hybridization for retrospective detection of aneuploidy in multiple myeloma. Gen. Chromosom. Cancer 1993; 7: 137–43
   PubMed Web of Science ®Google Scholar
• Facon T., Flactif M., Zandecki M., Bernardi F., Bauters F., LaÏ J. L. (1994) Fluorescence in situ Hibridization improves the detection of cytogenetic abnormalities in multiple myeloma. Thirty-sixth annual meeting of the ASH., Nashville, TN, December, 2–61994, Abstract 2076
   Google Scholar
• Sawyer J., Tricot G., Mattox S., Barlogie B. (1994) Monosomy 13 (-13) or abnormalities involving 14q (14q δ) are associated with poor prognosis in multiple myeloma. Thirty-sixth annual meeting of the ASH., Nashville, TN, December, 2–61994, Abstract 2078
   Google Scholar
• Drach J., Angerler J., Schuster J. Interphase cytogenetic studies in multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS). Thirty-sixth annual meeting of the ASH., Nashville, TN, December, 2–61994, Abstract 677
   Google Scholar
• Tabernero M. D., San Miguel J. F., GarcÍA-Sanz R., NÁJera M. L., GarcÍA-Isidoro M., PÉRez-SimÓN J. A., GonzÁLez M., Wiegant J., Raap A. K., OrfÃO A. Incidence of chromosome numerical changes in multiple myeloma. A FISH analysis using 15 chromosome specific probes, (Submitted)
   Google Scholar
• Dimopoulos M. A., Palumbo A., Delasalle K. B., Alexanian R. Primary plasma cell leukemia. Br. J. Haematol. 1994; 88: 754–759
   PubMed Web of Science ®Google Scholar
• Drach J., Gattringer C., Glassl H., Drach D., Huber H. The biological significance of the KI-67 growth fraction in multiple myeloma. Hematol. Oncol. 1992; 10: 125–134
   PubMed Web of Science ®Google Scholar
• Van Camp B., Durie B. G. M., Spier C., De Waele M., Van Riet I., Vela E., Frutiger V., Richter L. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990; 76: 377–382
   PubMed Web of Science ®Google Scholar
• San Miguel J. F., GonzÁLez M., GascÓN A., Moro M. J., HernÁNdez J. M., Ortega F., JimÉNez R., Guerras L., Romero M., Casanova F., Sanz M. A., SÁNchez J., Portero J. A., OrfÃO A. Immunophenotype heterogeneity of multiple myeloma: Influence on the biology and clinical course of the disease. Br J Haematol 1991; 77: 185–190
   PubMed Web of Science ®Google Scholar
• Durie B. G. M., Salmon S. E., Moon T. E. Pretreatment tumor mass, cell kinetics and prognostic in multiple myeloma. Blood 1980; 55: 364–369
   PubMed Web of Science ®Google Scholar
• Greipp P. R., Katzmann L. A., O'Fallon W. M., Kyle R. A. Value of beta-2-microglobulin levels and plasma cell labeling indices as prognostic factors in patients with newly diagnosed multiple myeloma. Blood 1988; 72: 219–223
   PubMed Web of Science ®Google Scholar
• Boccadoro M., Massaia M., Dianziani U., Pileri A. Multiple myeloma: biological and clinical significance of bone marrow plasma cell labeling index. Haematologica 1987; 72: 171–178
   PubMedGoogle Scholar
• San Miguel J. F., Garcia-Sanz R., GonzÁLez M., Moro M. J., HernÁNdez J. M., Borrego D., Carnero M., Casanova F., Ortega F., JimÉNez R., Portero J. A., OrfÃO A. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448–455
   PubMed Web of Science ®Google Scholar
• Greipp P. R., Lust J. A., O'Fallon M., Katzmann J. A., Witzig T. E., Kyle R. A. Plasma cell labeling index and β2-microglobulin predict survival independent of tymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382–3387
   PubMed Web of Science ®Google Scholar
• Greipp P. R., Gaillard J. P., Klein B. (1994) Independent prognostic value for plasma cell labeling index (PCL1), immunofluorescence microscopy plasma cell percent (IMPCP), beta 2-microglobulin (B2M), soluble interleukin-6 receptor (sIL-6R) and C-reactive protein (CRP) in myeloma trial E9487. Thirty-sixth annual meeting of the ASH., Nashville, TN, December, 2–61994, Abstract, 1524
   Google Scholar
• Riccardi A., Danova M., Wilson G. Cell kinetics in human malignancies studied with in vivo administration of bromod-eoxyuridine and flow cytometry. Cancer Res 1988; 48: 6238–6245
   PubMed Web of Science ®Google Scholar
• OrfÃO A., Ciudad J., GonzÁLez M., San Miguel J. F., GarcÍA A. R., LÓPez-Berges M. C., Ramos F., Del CaÑIzo M. C., RÍOs A., Sanz M., LÓPez-Borrasca A. Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia. Leukemia 1992; 6: 47–51
   PubMed Web of Science ®Google Scholar
• Vidriales M. B., OrfÃO A., LÓPez-Berges M. C., GonzÁLez M., Macedo A., Ciudad J., LÓPez A., GarcÍA M. A., HernÁNdez J., Borrego D., San Miguel J. F. Prognostic value of S-phase cells in AML patients. Br J Haematol 1995; 89: 342, 1995
   PubMed Web of Science ®Google Scholar
• OrfÃO A., GarcÍA-Sanz R., LÓPez-Berges M. C., Vidriales M. B., GonzÁLez M., San Miguel J. F. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 1994; 17: 332–339
   PubMedGoogle Scholar
• Shimazaki C., Gotoh H., Oku N., Inaba T., Murakami S., Oku N., Itoh K., Ura Y., Nakagawa M., Fujita N. Detection of minimal residual myeloma cells by dual parameter analysis of DNA and cytoplasmic immunoglobulin. Acta Haematol. 1991; 85: 20–25
   PubMed Web of Science ®Google Scholar